The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early-stage breast cancer.
 
Sara A. Hurvitz
Stock and Other Ownership Interests - Ideal Implant (I); ROM Tech (I)
Research Funding - Ambryx (Inst); Amgen (Inst); Arvinas (Inst); Bayer (Inst); Biomarin (Inst); Cascadian Therapeutics (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dignitana (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merrimack (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Phoenix Molecular Designs (Inst); Pieris Pharmaceuticals (Inst); Puma Biotechnology (Inst); Radius Health (Inst); Samumed (Inst); sanofi (Inst); Seagen (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Lilly
Other Relationship - Pfizer; Roche
 
Lisa S. Wang
No Relationships to Disclose
 
David Chan
No Relationships to Disclose
 
Vu Phan
No Relationships to Disclose
 
Thomas Lomis
No Relationships to Disclose
 
Nicholas Patrick McAndrew
Honoraria - Daiichi Sankyo
Consulting or Advisory Role - bioTheranostics; Daiichi Sankyo; Genomic Health; Novartis
Speakers' Bureau - Novartis
Research Funding - Daiichi Sankyo (Inst); Dizal Pharma (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Daiichi Sanko; Roche; TRIO US
 
Laura Spring
Consulting or Advisory Role - Avrobio; Novartis; Puma Biotechnology
Research Funding - Merck (Inst); Philips Healthcare (Inst)
 
Merry L. Tetef
No Relationships to Disclose
 
Deborah Villa
No Relationships to Disclose
 
Steven Applebaum
No Relationships to Disclose
 
Erin Chamberlain
No Relationships to Disclose
 
Shaker R. Dakhil
No Relationships to Disclose
 
Brian Anthony DiCarlo
Honoraria - bioTheranostics
Research Funding - ARMO BioSciences (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb BMS CA209-370 (Inst); Bristol-Myers Squibb BMS CA209-370 (Inst); Bristol-Myers Squibb BMS CA209-602 (Inst); Bristol-Myers Squibb BMS CA209-627 (Inst); Bristol-Myers Squibb BMS CA209-655 (Inst); Bristol-Myers Squibb BMS CA209-714 (Inst); Bristol-Myers Squibb BMS CA209-817 (Inst); Bristol-Myers Squibb BMS CA209-920 (Inst); Halozyme (Inst); Novartis (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Syndax (Inst); Takeda (Inst)
 
David D. Kim
No Relationships to Disclose
 
Evangelia K. Kirimis
No Relationships to Disclose
 
William E. Lawler
No Relationships to Disclose
 
Aashini K. Master
No Relationships to Disclose
 
Christine Kivork
No Relationships to Disclose
 
James Chauv
No Relationships to Disclose
 
Aditya Bardia
Consulting or Advisory Role - bioTheranostics; Daiichi Sankyo/Astra Zeneca; Foundation Medicine; Genentech; Genentech/Roche (Inst); Immunomedics; Immunomedics (Inst); Innocrin Pharma (Inst); Merck; Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Philips Healthcare; Puma Biotechnology; Radius Health; Radius Health (Inst); Sanofi; Spectrum Pharmaceuticals
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Genentech (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Sanofi (Inst)